Header cover image

Swiss Biotech Stocks

Results

15

1 new

Even though biotechnology stocks can be very risky, they can also offer some of the biggest rewards with huge profits on offer when you find the right one. The companies below all have reasonable balance sheets and value, giving the best chance of finding a gem.

15 companies

Roche Holding

Market Cap: CHF 211.2b

Engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand.

ROG

CHF 263.40

7D

1.7%

1Y

12.4%

Novartis

Market Cap: CHF 182.8b

Engages in the research, development, manufacture, distribution, marketing, and sale of pharmaceutical medicines in Switzerland and internationally.

NOVN

CHF 93.29

7D

3.5%

1Y

-0.6%

Galderma Group

Market Cap: CHF 24.3b

Operates as a dermatology company worldwide.

GALD

CHF 102.20

7D

4.3%

1Y

36.9%

Sandoz Group

Market Cap: CHF 17.2b

Develops, manufactures, and markets generic pharmaceuticals and biosimilars worldwide.

SDZ

CHF 40.05

7D

5.9%

1Y

25.6%

Siegfried Holding

Market Cap: CHF 4.2b

Engages in contract development and manufacturing of active pharmaceutical ingredient (API) and finished dosage forms worldwide.

SFZN

CHF 96.60

7D

1.7%

1Y

9.8%

Bachem Holding

Market Cap: CHF 3.9b

Provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide.

BANB

CHF 52.30

7D

-1.0%

1Y

-41.7%

SKAN Group

Market Cap: CHF 1.6b

Provides isolators, cleanroom devices, and decontamination processes for pharmaceutical and chemical industries in Europe, the Americas, Asia, and internationally.

SKAN

CHF 72.30

7D

5.9%

1Y

-9.9%

Cosmo Pharmaceuticals

Market Cap: CHF 876.0m

Focuses on the development and commercialization products for gastroenterology, dermatology, and healthtech worldwide.

COPN

CHF 54.70

7D

3.0%

1Y

-24.2%

PolyPeptide Group

Market Cap: CHF 642.1m

Operates as a contract development and manufacturing company in Europe, the United States, and India.

PPGN

CHF 19.46

7D

-2.7%

1Y

-40.6%

Basilea Pharmaceutica

Market Cap: CHF 549.0m

Engages in the discovering, developing, and commercializing drugs for bacterial or fungal infections.

BSLN

CHF 44.75

7D

2.6%

1Y

3.8%

Santhera Pharmaceuticals Holding

Market Cap: CHF 169.6m

A specialty pharmaceutical company, together with its subsidiaries, develops and sells medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the Europe, North America, and Asia.

SANN

CHF 13.18

7D

-0.6%

1Y

42.2%

Newron Pharmaceuticals

Market Cap: CHF 155.1m

A biopharmaceutical company, discovers and develops novel therapies for patients with diseases of the central and peripheral nervous system in Italy and the United States.

NWRN

CHF 7.77

7D

-4.9%

1Y

-22.9%

Molecular Partners

Market Cap: CHF 120.4m

A clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland.

New

MOLN

CHF 3.27

7D

-4.3%

1Y

-3.8%

Xlife Sciences

Market Cap: CHF 117.1m

Focuses on the development and commercialization of research projects in the life sciences sector.

XLS

CHF 20.40

7D

2.0%

1Y

-40.2%

Relief Therapeutics Holding

Market Cap: CHF 26.8m

A biopharmaceutical company, engages in identification, development, and commercialization of novel, patent protected products for the treatment of dermatological, metabolic, and pulmonary rare diseases in Switzerland, Europe, North America, and internationally.

RLF

CHF 2.13

7D

1.2%

1Y

70.4%